Rhythm Pharmaceuticals, Inc.
setmelanotide
acquired hypothalamic obesity
Resolved
110days ago
Phase 3 readout · Mar 19, 2026
What's at stake
Phase 3 trial results for setmelanotide in acquired hypothalamic obesity are due Mar 19, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“The approval is supported by the positive pivotal Phase 3 TRANSCEND trial of setmelanotide in 142 patients with acquired HO. The global study met its primary endpoint, with a statistically significant -18.4% placebo-adjusted reduction in bo”